Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreens (WBA) has joined Pulse by NABP™, a digital platform designed to enhance visibility in the drug supply chain and protect patients from counterfeit medications. This move will assist Walgreens with Drug Supply Chain Security Act (DSCSA) compliance and ensure its prescription medication suppliers are properly licensed.
The DSCSA, enacted in 2013, aims to improve pharmaceutical supply chain safety and prevent harmful drugs from entering the market. Pulse will help Walgreens verify that only legitimate and authorized trading partners provide medications to its patients.
John Colaizzi, VP of pharmacy practice at Walgreens, emphasized the company's commitment to patient safety. NABP is initially rolling out Pulse to select supply chain users, with plans to offer free registration to all prescription drug supply chain members to facilitate DSCSA-required interoperability.
Walgreens Boots Alliance (Nasdaq: WBA) has announced the schedule for its fourth quarter and 2024 fiscal year-end earnings release. The company will disclose its financial results on Tuesday, October 15, 2024, at 7 a.m. ET. Following the release, WBA management will host a one-hour conference call at 8:30 a.m. ET to discuss the results. Investors and interested parties can access the live simulcast of the conference call through the WBA investor relations website. For those unable to attend the live call, a replay will be available on the website for 12 months after the event.
Walgreens has launched a new premium skin care line that offers high-quality products at affordable prices. The collection includes cleansers, exfoliants, moisturizers, sunscreens, and serums, with prices ranging from $5.99 to $22.99. These products are at least 50% less expensive than comparable premium brands. Heather Hughes, group vice president at Walgreens, emphasizes that this line is a game-changer for budget-conscious consumers seeking luxury skincare.
The new line features products like a Gentle Cleanser ($10.49), 2% BHA Liquid Exfoliant ($11.99), and Super Invisible SPF40 ($14.99). Walgreens also introduced four serums priced at $5.99 each, targeting specific skin concerns. This initiative aligns with Walgreens' focus on women's health and beauty, aiming to provide personalized, affordable solutions to its customers.
Walgreens has announced that Ramita Tandon, Chief Clinical Trials Officer, will deliver a keynote presentation at TD Cowen's 9th Annual FutureHealth Conference on Tuesday, Sept. 10 at 4:10 p.m. EST. This event highlights Walgreens' involvement in healthcare innovation and clinical research.
The presentation will be webcast live, allowing investors and interested parties to tune in remotely. An audio portion of the presentation will be accessible through the Walgreens Boots Alliance investor relations website. This participation in the conference demonstrates Walgreens' commitment to sharing insights on future health trends and their role in advancing healthcare solutions.
Bilt Rewards, known for transforming rent payments into rewards, has expanded its neighborhood rewards program through a collaboration with Walgreens (WBA). The partnership introduces an innovative 'Automatic Healthcare Savings' program, allowing customers to easily apply FSA or HSA benefits to purchases at Walgreens.
Key features include:
- Automatic FSA/HSA savings on eligible items
- Enhanced rewards: 1x Bilt points on all Walgreens purchases, 2x on Walgreens-branded items, and 100 points on prescription refills
- Upcoming complimentary photo prints at Walgreens pharmacies
This collaboration aims to simplify healthcare expenses, address the $4 billion in lost FSA dollars annually, and enhance the customer experience at Walgreens. The program is available immediately, with photo prints launching soon.
Walgreens WBA and BARDA have formed a strategic partnership to enhance decentralized clinical trials (DCTs) in the US. This $100 million, five-year collaboration aims to address barriers in DCT access and conduct trials through the D-COHRe program. Walgreens will leverage its clinical trial ecosystem, which has reached over 5 million potential participants since 2022, consistently meeting recruitment goals and surpassing national averages for diverse participant recruitment.
The partnership seeks to strengthen US decentralized clinical research capabilities, support FDA-regulated product development, and evaluate medical countermeasures for public health emergencies. Walgreens' approach combines its physical footprint with a decentralized platform to engage patients conveniently, positioning it as an ideal partner for enhancing DCTs during public health crises.
Walgreens (WBA) has announced two key leadership appointments to enhance its retail and customer experience team. Tracey Koller joins as Senior Vice President and Chief Merchandising Officer, while Sharmila Sudhakar takes on the role of Group Vice President and Head of Walgreens Digital Commerce. These appointments are part of Walgreens' strategy to turnaround its business, focusing on improving the front-of-store and omnichannel experience while driving in-store efficiencies.
Koller, with over 30 years of experience in omni-channel merchandising and operations, will lead the merchandising strategy across all categories. Sudhakar, a tenured omni-retail executive, will be responsible for driving digitally initiated revenue growth and strengthening digital engagement through omni-channel solutions. Both leaders are set to begin their new roles in late August, bringing their extensive expertise to support Walgreens' growth and success in delivering an efficient, highly relevant customer experience.
Walgreens Boots Alliance (Nasdaq: WBA) has announced the pricing of a $750 million underwritten public offering of senior unsecured notes, due in 2029 with an interest rate of 8.125%. The sale is expected to close on August 12, 2024, subject to customary conditions. WBA plans to use the net proceeds, along with cash on hand, to repay or retire its outstanding 3.800% notes due in 2024, with any remaining funds allocated for general corporate purposes. The joint book-running managers for the offering are J.P. Morgan Securities , Wells Fargo Securities, , and BofA Securities, Inc.
This Must Be the Place (TMBTP), an overdose prevention non-profit, and Walgreens have partnered to expand access to naloxone at music and art festivals. Walgreens has facilitated the donation of 12,000 units of Walgreens Brand Naloxone HCI Nasal Spray, valued at over $400,000, to TMBTP for distribution at festivals. This initiative aims to educate attendees about the opioid crisis and overdose response.
TMBTP will have booths at festivals to distribute free naloxone kits and provide education. Walgreens offers naloxone at a lower price than comparable national brands in its stores, serving as a critical access point for its 10 million daily customers. This partnership aligns with Walgreens' commitment to addressing the opioid overdose crisis and improving community health.
Walgreens and Instacart have announced a nationwide collaboration to accept SNAP/EBT payments online at over 7,500 Walgreens stores, including 100+ Duane Reade locations in New York. This initiative allows customers to purchase thousands of SNAP-eligible products for same-day delivery via Instacart, broadening food access for over 40 million SNAP/EBT beneficiaries.
The partnership aims to enhance Walgreens' front-of-store experience and create omnichannel solutions while improving in-store efficiencies. Customers can now order SNAP-eligible items from Walgreens through Instacart's website or mobile app, selecting their SNAP EBT card as a payment method and allocating their benefits to eligible items at checkout.
FAQ
What is the current stock price of Walgreen Boots (WBA)?
What is the market cap of Walgreen Boots (WBA)?
